66
Transcenta
6628.HK·HKEXSuzhou CNFounded 2014400 employees
Micro CapbiotechPublicOncologyImmunology
Platform: Bispecific
Market Cap
$0.2B
All Drugs
2
Clinical Trials
2
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (6628.HK)
Loading 6628.HK stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Nidatuximab | 662-8401 | Preclinical | 1 | MALT1 | GBMMyelofibrosis | ||
| Lirazumab | 662-2443 | Phase 2 | 1 | FXIa | ASRB |
SEC Filings & Financial Documents
SEC filings are not available for HKEX-listed companies.
Transcenta trades on HKEX (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (2)